The Search for Certainty: What Google Reveals About How We Think About Health
In the waiting rooms of America, a familiar ritual plays out every day. A patient glances at their phone, opens ...
From Burden to Breakthrough: Why 81% of Physicians Are Ready to Embrace AI
In a profession built on human connection, the growing embrace of artificial intelligence might seem counterintuitive. But when 81% of ...
Tariffs and Trade-Offs: How Trump’s China Tariff Hike Could Ripple Through U.S. Healthcare
The announcement landed like a stone in murky waters — rippling outward in waves no one could fully map. In ...
What Happens When the Match Ends? States Brace for Impact as CMS Shifts Medicaid Funding Rules
When a federal agency changes the way money flows, the effects aren’t always immediate — but they’re often profound. In ...
Mpox and the Next Global Threat: Why We Can’t Afford to Look Away
Unlike COVID-19, Mpox didn’t spark immediate worldwide lockdowns. There were no international travel bans or sweeping mask mandates. But for ...
Silent Scars: Uncovering the Cancer Risk Among U.S. Veterans Exposed to Burn Pits in Iraq
When U.S. troops were deployed to Iraq in the early 2000s, few could have imagined that the very air they ...
Combating Vaccine Revisionism: A Stand for Science and Public Trust
There is a subtle but dangerous form of misinformation spreading — not loud and conspiratorial, but quiet and insidious. It’s ...
Where Medicine Meets Morality: How Specialty Societies Responded to the Gaza-Israel Conflict
In the early days of the Gaza-Israel conflict, images of devastation filled screens and newspapers around the world. Hospitals overwhelmed, ...
Understanding the Hidden Risks: Why Some Children Experience Severe Illness from RSV
A small, wiry cough. A child’s flushed cheeks. A worried parent clutching an ER intake clipboard. These are the moments ...
Unseen Consequences: How COVID-19 in Children May Impact Kidney Health
The narrative around COVID-19 and children has long been shaped by a sense of guarded relief. While adults—particularly the elderly ...
Private Equity’s Quiet Expansion into Disability Care
There’s a quiet revolution happening in the disability services sector—one that is rarely covered in mainstream media but carries far-reaching ...
The Flexner Report and the Rise of Pharmaceutical Hegemony
In 1910, Abraham Flexner published a report that would forever alter the course of American medicine. Commissioned by the Carnegie ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read morePopular
-
The IRA’s Drug Negotiation Mechanism Meets the Rebate Industrial Complex
-
Retatrutide: The Weight Loss Drug Everyone Wants—But Can’t Officially Get
-
Growth Hormone Secretagogues and the Longevity Trade-Off
-
GLP-1 Agonists Beyond Obesity: The Expanding Therapeutic and Optimization Frontier
-
The Second Reader That Never Sleeps: Large Language Models and Clinical Decision-Making
